MondegarAI
← Tracker

Institutional

Commodore Capital LP

CIK 0001831942
$1.73B
Reported AUM
36
Positions
Q1 2026
Period
2026-05-15
Filed

The Brief · Commodore Capital LP · Q1 2026

AI · grounded in 13F

Commodore Capital LP exited its position in Terns Pharmaceuticals Inc 430, reducing exposure by $59.6M. The fund established new positions in Erasca Inc ERAS and Damora Therapeutics Inc DMRA, adding $51.4M and $50.2M respectively. Other notable activity includes new stakes in Definium Therapeutics Inc DFTX and Eyepoint Inc EYPT, alongside a full exit from Oruka Therapeutics Inc.

Portfolio · Q1 2026

RLAY$169.2MALKS$148.5MELVN$128.4MCOGT$111.2MSYRE$96.5MTYRA$94.8MCLDXNUVLAMLXKYMRANROPHVSOther$552.6MCL

Top holdings

QoQ vs Q4 2025

#StockIssuerPriceDay %1Y Gr.5Y Gr.Value% of bookΔ shares (QoQ)Status
1RLAYRELAY THERAPEUTICS INC$13.52-7.02%302.38%-58.32%$169.2M9.79%HELD
2ALKSALKERMES PLC$42.80-1.34%34.97%65.44%$148.5M8.59%+650,000+18.3%
3ELVNENLIVEN THERAPEUTICS INC$34.71-2.20%67.36%60.99%$128.4M7.43%1,417,809−30.2%
4COGTCOGENT BIOSCIENCES INC$31.02-5.40%356.18%417.00%$111.2M6.43%+691,162+31.5%
5SYRESPYRE THERAPEUTICS INC$73.65-6.15%334.00%-51.94%$96.5M5.58%475,865−19.9%
6TYRATYRA BIOSCIENCES INC$26.64-1.99%152.51%18.98%$94.8M5.48%900,000−26.7%
7CLDXCELLDEX THERAPEUTICS INC NEW$28.62-4.38%34.05%-34.58%$85.5M4.95%+131,616+5.1%
8NUVLNUVALENT INC$90.95-3.27%16.57%149.66%$85.4M4.94%+283,600+51.6%
9AMLXAMYLYX PHARMACEUTICALS INC$13.32-6.92%149.91%-59.51%$78.5M4.54%HELD
10KYMRKYMERA THERAPEUTICS INC$74.13-0.64%55.67%23.18%$62.5M3.61%HELD
11ANROALTO NEUROSCIENCE INC$18.26-8.84%610.51%18.96%$61.2M3.54%+900,000+49.4%
12PHVSPHARVARIS N V$31.09-1.71%85.28%74.96%$54.2M3.14%+29,525+1.6%
13ERASERASCA INC$11.97-9.80%648.13%-49.94%$51.4M2.97%+3,175,000NEW
14DMRADAMORA THERAPEUTICS INC$21.01-5.83%538.60%-80.41%$50.2M2.91%+1,939,000NEW
15XENEXENON PHARMACEUTICALS INC$51.73-2.38%63.50%199.54%$48.0M2.78%975,000−54.2%
16DFTXDEFINIUM THERAPEUTICS INC$23.55-4.23%202.31%-48.69%$37.8M2.19%+2,000,000NEW
17LBRXLB PHARMACEUTICALS INC$28.53-1.28%69.82%76.88%$37.0M2.14%HELD
18EYPTEYEPOINT INC$11.78-3.92%31.77%43.31%$36.4M2.11%+2,825,000NEW
19NRIXNURIX THERAPEUTICS INC$14.64-4.19%14.55%-52.37%$35.3M2.04%HELD
20CRVSCORVUS PHARMACEUTICALS INC$11.12-5.12%184.40%432.06%$33.0M1.91%+2,258,735NEW
21ASMBASSEMBLY BIOSCIENCES INC$22.90-5.02%41.01%-45.00%$27.8M1.61%HELD
22CATXPERSPECTIVE THERAPEUTICS INC$3.03-6.77%-8.73%-56.09%$26.4M1.53%+6,336,782NEW
23SLNOSOLENO THERAPEUTICS INC$53.010.00%-29.80%288.35%$21.8M1.26%547,568−45.6%
24OCULOCULAR THERAPEUTIX INC$8.25-6.25%-8.54%-25.07%$21.8M1.26%+2,575,000NEW
25IPSCCENTURY THERAPEUTICS INC$2.13-3.18%245.78%-92.69%$19.7M1.14%+8,695,652NEW
26ZURAZURA BIO LTD$3.40-7.36%169.84%-50.07%$19.3M1.12%+3,250,000NEW
27SABSSAB BIOTHERAPEUTICS INC$3.38-2.59%86.74%-96.59%$16.9M0.98%HELD
28PALIPALISADE BIO INC$1.74-9.84%148.57%-99.92%$12.6M0.73%4,263,938−37.3%
29KPTIKARYOPHARM THERAPEUTICS INC$9.080.11%102.23%-92.73%$10.9M0.63%+1,950,000NEW
30IKTINHIBIKASE THERAPEUTICS INC$1.63-1.81%-16.84%-88.03%$9.1M0.52%HELD
31ANTXAN2 THERAPEUTICS INC$3.82-8.39%$8.0M0.46%+2,333,713NEW
32PEPGPEPGEN INC$1.41-4.73%$7.9M0.46%+1,075,000+31.6%
33AVTXAVALO THERAPEUTICS INC$13.10-3.75%$7.2M0.42%HELD
34HLXCHELIX ACQUISITION CORP III$10.24-0.10%$5.1M0.29%+500,000NEW
35LONALEONABIO INC$8.22-4.53%$4.8M0.28%HELD
36RLMDRELMADA THERAPEUTICS INC$5.95-5.71%$4.4M0.26%+633,901NEW
37430TERNS PHARMACEUTICALS INC1,475,000EXITED
38ORKAORUKA THERAPEUTICS INC$60.14-3.44%1,753,054EXITED
39PTGXPROTAGONIST THERAPEUTICS INC$97.38-5.26%450,000EXITED
40CTMXCYTOMX THERAPEUTICS INC$3.00-5.66%7,692,300EXITED
41BRD1EURMIND MEDICINE MINDMED INC2,000,000EXITED
42CNTACENTESSA PHARMACEUTICALS PLC$39.62-0.45%1,000,000EXITED
43REPLREPLIMUNE GROUP INC$9.47-4.05%1,425,000EXITED
44CTNMCONTINEUM THERAPEUTICS INC$11.49-6.89%816,326EXITED
45RAPTRAPT THERAPEUTICS INC250,000EXITED
46DRUGBRIGHT MINDS BIOSCIENCES INC$69.00-7.38%18,851EXITED

Source: SEC EDGAR · accession 0001831942-26-000025. 13F discloses long positions only — shorts, foreign equities, and options are excluded.